Sign in

CIK 0001652130 · Large accelerated filer

Intellia Therapeutics, Inc.

Sign in to watch
Ticker
NTLA
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
364785571
Phone
857-285-6200
Business address
400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
  1. 4 Planned sale President and CEO sold 9,000 shares at $11.99 ($107,910)
  2. 4 Grant or award EVP, Chief Medical Officer acquired 199,822 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market sale VP, Chief Accounting Officer sold 1,864 shares at $12.43 ($23,170)
  5. 4 Planned sale President and CEO sold 22,675 shares at an average $12.65 ($286,819)
  6. 4 Open-market sale EVP, Chief Financial Officer sold 8,111 shares at $11.25 ($91,249)
  7. 4 Open-market sale VP, Chief Accounting Officer sold 2,641 shares at $16.78 ($44,316)
  8. 4 Planned sale EVP, Chief Financial Officer sold 4,677 shares at $18.00 ($84,186)
  9. 4 Grant or award Director acquired 9,200 shares (grant or award)
  10. 4 Grant or award Director acquired 9,200 shares (grant or award)
  11. 4 Grant or award Director acquired 9,200 shares (grant or award)
  12. 4 Grant or award Director acquired 9,200 shares (grant or award)
  13. 4 Grant or award Director acquired 9,200 shares (grant or award)
  14. 4 Grant or award Director acquired 9,200 shares (grant or award)
  15. 4 Grant or award Director acquired 9,200 shares (grant or award)
  16. 4 Grant or award President and CEO acquired 156,400 shares (grant or award)
  17. 4 Open-market sale EVP, General Counsel sold 1,211 shares at $13.78 ($16,688)
  18. 4 Grant or award EVP, Chief Medical Officer acquired 9,943 shares (grant or award)
  19. 4 Grant or award EVP, Chief Financial Officer acquired 61,280 shares (grant or award)
  20. 4 Grant or award EVP, Chief Scientific Officer acquired 39,200 shares (grant or award)

Page 1 of 18 · 353 filings